Sp803

USING IMPLEMENTATION SCIENCE TO IMPROVE THE EQUITY OF HEPATOLOGY CARE

Date
May 8, 2023
Explore related products in the following collection:

Society: DDW

LIVE STREAM SESSION

Presenter

Speaker Image for Shari Rogal
VA Pittsburgh Healthcare System

Tracks

Related Products

Thumbnail for IL-17 SUPPRESSES PATHOGENESIS AND STEM CELL ACTIVATION WITHIN THE CONTEXT OF CHRONIC <i>HELICOBACTER PYLORI</i> INFECTION
IL-17 SUPPRESSES PATHOGENESIS AND STEM CELL ACTIVATION WITHIN THE CONTEXT OF CHRONIC <i>HELICOBACTER PYLORI</i> INFECTION
BACKGROUND: Perianal fistulae are highly morbid complications of Crohn’s disease (CD) with a cumulative incidence of 20-25%; despite demonstrated efficacy of infliximab treatment, estimates of complete resolution are only 20-30%. Ultimately, 20% of patients will require proctectomy…
Thumbnail for PANEL DISCUSSION
PANEL DISCUSSION
SOCIETY: DDW
Thumbnail for MULTIMODAL SINGLE CELL ANALYSES REVEAL PATHOGENIC FIBROBLASTS IN PERIANAL FISTULA
MULTIMODAL SINGLE CELL ANALYSES REVEAL PATHOGENIC FIBROBLASTS IN PERIANAL FISTULA
BACKGROUND: Perianal fistulae are highly morbid complications of Crohn’s disease (CD) with a cumulative incidence of 20-25%; despite demonstrated efficacy of infliximab treatment, estimates of complete resolution are only 20-30%. Ultimately, 20% of patients will require proctectomy…
Thumbnail for IMMUNE EDITING IN THE INVASIVE MARGIN AND NODE DEPOSITS OF COLORECTAL CANCER SELECTS FOR CELLULAR NEIGHBOURHOODS ENRICHED IN PDL1+ CANCER CELLS
IMMUNE EDITING IN THE INVASIVE MARGIN AND NODE DEPOSITS OF COLORECTAL CANCER SELECTS FOR CELLULAR NEIGHBOURHOODS ENRICHED IN PDL1+ CANCER CELLS
BACKGROUND: Perianal fistulae are highly morbid complications of Crohn’s disease (CD) with a cumulative incidence of 20-25%; despite demonstrated efficacy of infliximab treatment, estimates of complete resolution are only 20-30%. Ultimately, 20% of patients will require proctectomy…